Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy: A Prospective Multi-Centre Agreement Clinical Trial (CAN-ICE)
Marc Fortin, Moïshe Liberman, Antoine Delage, Geneviève Dion, Simon Martel, Fabien Rolland, Thibaud Soumagne, Sylvain Trahan, Deborah Assayag, Elisabeth Albert, Margaret M. Kelly, Kerri A. Johannson, Z. Guenther, Charles Leduc, H. Manganas, Julie Prénovault, Steeve Provencher
Abstract
Abstract Rationale Transbronchial cryobiopsy (TBCB) for the diagnosis of interstitial lung disease (ILD) has shown promising results, but prospective studies with matched surgical lung biopsy (SLB) have yielded conflicting results. Objectives We aimed to assess within- and between-center diagnostic agreement between TBCB and SLB at both the histopathologic and multidisciplinary discussion (MDD) levels in patients with diffuse ILD. Methods In a multicenter prospective study, we performed matched TBCB and SLB in patients referred for SLB. After a blinded review by three pulmonary pathologists, all cases were reviewed by three independent ILD teams in an MDD. MDD was performed first with TBCB, then with SLB in a second session. Within-center and between-center diagnostic agreement was evaluated using percentages and correlation coefficients. Measurements and Main Results Twenty patients were recruited and underwent contemporaneous TBCB and SLB. Within-center diagnostic agreement between TBCB–MDD and SLB–MDD was reached in 37 of the 60 (61.7%) paired observations, resulting in a Cohen’s κ value of 0.46 (95% confidence interval [CI], 0.29–0.63). Diagnostic agreement increased among high-confidence or definitive diagnoses on TBCB–MDD (21 of 29 [72.4%]), but not significantly, and was more likely among cases with SLB–MDD diagnoses of idiopathic pulmonary fibrosis than fibrotic hypersensitivity pneumonitis (13 of 16 [81.2%] vs. 16 of 31 [51.6%]; P = 0.047). Between-center agreement for cases was markedly higher for SLB–MDD (κ = 0.71 [95% CI, 0.52–0.89]) than TBCB–MDD (κ = 0.29 [95% CI, 0.09–0.49]). Conclusions This study demonstrated moderate TBCB–MDD and SLB–MDD diagnostic agreement for ILD, while between-center agreement was fair for TBCB–MDD and substantial for SLB–MDD. Clinical trial registered with www.clinicaltrials.gov (NCT 02235779).